Company intelligence / Profile preview

Heking Pharmaceutical Technology

Ownership: Private
Development stage: Other

Overview

Heking Med is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology and autoimmune diseases. The company leverages its internal R&D capabilities to target well-validated pathways such as MET, FGFR, and JAK, with a primary focus on addressing unmet medical needs in solid tumors and inflammatory conditions. Its lead candidate, HK-010, is a highly selective MET inhibitor currently undergoing clinical evaluation for various cancers. Heking Med aims to provide high-quality, affordable precision medicines through a combination of independent innovation and strategic collaborations.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Heking Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heking Pharmaceutical Technology.